Clinical Trials Logo

Stroke, Acute clinical trials

View clinical trials related to Stroke, Acute.

Filter by:

NCT ID: NCT05559398 Not yet recruiting - Stroke, Acute Clinical Trials

Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study

GREEN
Start date: October 10, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Emergent reperfusion is the main goal for acute ischemic stroke therapy (AIS). Endovascular therapy (EVT) is recommended within 6 hrs of stroke onset, and up to 24 hrs following perfusion imaging criteria. Despite the major benefit associated with MT, more than 50% of the patients remain disabled at 3 months. Reperfusion rates after MT are critical to determine functional outcome. However, complete reperfusion is obtained in only 50 % of the patients, due to, at least in part, erratic emboli and/or no-reflow processes. The aim of this study is to evaluate the efficacy of glenzocimab in addition to EVT and compared to EVT plus placebo, whether or not associated with ntravenous thrombolysis (IVT), on functional outcome at day 90.

NCT ID: NCT05534360 Not yet recruiting - Stroke, Acute Clinical Trials

Tenecteplase Treatment in Ischemic Stroke Registry

TETRIS
Start date: September 2022
Phase:
Study type: Observational [Patient Registry]

The Tenecteplase Treatment in Acute Ischemic Stroke (TETRIS) Registry is multicenter ambispective observational study of patients with acute ischemic stroke who received intravenous thrombolysis with Tenecteplase

NCT ID: NCT05522569 Temporarily not available - Clinical trials for Acute Ischemic Stroke

Expanded Access Multi-Patient Experimental Treatment Involving Allogeneic Human Mesenchymal Stem Cells (hMSCs) in Subjects With Acute Ischemic Stroke (EXPAND)

EXPAND
Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to use an intravenous infusion of allogeneic human mesenchymal stem cells (Allo-hMSCs) to treat an acute ischemic stroke condition.

NCT ID: NCT05494034 Recruiting - Stroke Clinical Trials

Yield of Implantable Cardiac Monitoring Device in Patients With Acute Ischemic Stroke.

Start date: May 5, 2023
Phase: N/A
Study type: Interventional

In this prospective cohort study, the investigators aim to investigate the incidence of ICM-detected AF in unselected ischemic stroke patients and its association with anticoagulation initiation and stroke recurrence.

NCT ID: NCT05476913 Recruiting - Pulmonary Embolism Clinical Trials

GEKO Venous Thromboembolism Prevention Study

Start date: July 6, 2023
Phase: N/A
Study type: Interventional

This multicentre, randomised geko™ venous thromboembolism (VTE) prevention study will prospectively collect clinical data on VTE occurrences in immobile patients after stroke, who will be randomised, on a 1:1 allocation, to receive either standard of care (Intermittent Pneumatic Compression) or geko™ neuromuscular electrostimulation device. The aim is to assess the prevention of VTE during a follow-up period of 90 days (three months) post-randomisation.

NCT ID: NCT05466864 Recruiting - Stroke, Acute Clinical Trials

Screening of OSA in Hospitalized Stroke Patients Using BSP

Start date: May 4, 2022
Phase: N/A
Study type: Interventional

Obstructive sleep apnea (OSA) is prevalent in patients with stroke and has a negative effect on outcomes by predisposing them to recurrent stroke, increasing mortality, and so forth. Therefore, it is extremely important to identify OSA in patients with stroke. Wearable devices can greatly reduce the manpower and material requirements of traditional laboratory-based polysomnography (PSG). With Photoplethysmography (PPG) technology and neural network algorithms, the Belun ring and the sleeping platform not only can detect blood oxygen, and heart rate but also can identify sleep stage and estimate the severity of sleep apnea. In this study, inpatients with acute ischemic stroke in the hospital will proceed with three nights test for recording the parameters of the autonomic nervous system in the acute phase, evaluate whether sleep apnea and the feasibility of the Belun sleep platform. It is important that early recognition of OSA and prompt treatment, which can potentially improve OSA-associated adverse outcomes, as well as understanding the degree of autonomic nervous function impairment for patients with acute ischemic stroke. After smoothing this process, it can help clinicians more accurately comprehend the condition, timing of admission, and discharge.

NCT ID: NCT05465980 Not yet recruiting - Stroke, Acute Clinical Trials

Development and Validation of the Prediction Model for Cognitive Impairment

Start date: September 1, 2022
Phase:
Study type: Observational

According to the "Chinese Stroke Report" released in 2020, the incidence of stroke in China is 1114.8/100,000, acute ischemic stroke (AIS) accounts for 70% to 80% of the total number of stroke population, and elderly stroke patients are up to 2/3. About 1/3 of stroke patients would experience post-stroke cognitive impairment (PSCI), which seriously affected patients' quality of life and survival time, and increases disease and economic burden. Therefore, early identification, assessment, prevention and intervention of PSCI, and improvement of patients' quality of life and prognosis have become the focus of clinical research. This is a prospective cohort study. We intend to: (1) continuously collect elderly AIS patients who will be admitted to the Department of Neurology, The Department of Rehabilitation and the Department of Gerontology of Shenzhen Second People's Hospital from 2022 year to 2024 year; (2) collect baseline and follow-up data, and build a prediction model for cognitive impairment in elderly AIS patients; (3) internal validation using Bootstrap model; (4) collect the data of the elderly AIS patients who will be admitted to Shenzhen Longhua District People's Hospital andShenzhen Longgang Central Hospital, and conduct external validation; (5) evaluate the predictive efficacy of the model.

NCT ID: NCT05447728 Recruiting - Stroke, Acute Clinical Trials

Feasibility of Stroke Screening Tools in Cardiac Surgery Patients

PESST-Cardiac
Start date: July 4, 2022
Phase:
Study type: Observational

Patients undergoing cardiac surgery have a higher risk of postoperative stroke than patients undergoing non-cardiac surgery. Our ability to detect postoperative stroke in this population lags behind other postoperative complications which impacts outcomes for patients eligible for medical intervention. Screening tools have been successful in detecting prehospital stroke with good accuracy, but these tools have not been validated in a postoperative setting. The aim of this pilot study is to use determine the feasibility of using prehospital stroke scales in a post-cardiac surgery population, identify barriers for scale completion, and determine non-stroke factors that may affect screening scores.

NCT ID: NCT05419193 Recruiting - Stroke Clinical Trials

PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)

PRO-CHASE
Start date: February 21, 2023
Phase: Phase 2
Study type: Interventional

Stroke-associated pneumonia (SAP) is a grave complication of stroke and one of the most important predictors for patients' poor outcomes. Stroke associated pneumoniaSAP and other infections limited the overall efficacy of stroke management. Increasing evidence suggests that sympathetic nervous system activity contributes to post post-stroke immunosuppression and emergence of infections. This study is designed to test the safety and efficacy of an adrenergic β receptor blocker propranolol in reducing SAP in hemorrhagic stroke patients, in a multi-center, randomized, open-labeled, end point-blinded, trial.

NCT ID: NCT05417802 Active, not recruiting - Stroke, Acute Clinical Trials

Surveying Patient's Interest in Robotic Rehabilitation Device

Start date: December 8, 2021
Phase:
Study type: Observational

This is a survey study to understand the stroke survivor's interest in robotic training. Investigators will use a questionnaire and show a video of robotic therapy to ask questions on their interest.